On April 30, 2024, XTL Biopharmaceuticals Ltd. held an Extraordinary General Meeting where shareholders approved several proposals, including granting options totaling 138,500 to executives and re-electing a director. Additionally, a private placement of $1.5 million was approved, contingent on an acquisition.